Success Metrics

Clinical Success Rate
87.4%

Based on 26,137 completed trials

Completion Rate
87%(26137/29893)
Active Trials
4,644(11%)
Results Posted
47%(12404 trials)
Terminated
3,756(9%)

Phase Distribution

Ph phase_2
12,598
31%
Ph phase_4
4,096
10%
Ph not_applicable
6,621
16%
Ph early_phase_1
557
1%
Ph phase_1
7,935
20%
Ph phase_3
8,711
21%

Phase Distribution

8492

Early Stage

12598

Mid Stage

12807

Late Stage

Phase Distribution40518 total trials
Early Phase 1First-in-human
557(1.4%)
Phase 1Safety & dosage
7,935(19.6%)
Phase 2Efficacy & side effects
12,598(31.1%)
Phase 3Large-scale testing
8,711(21.5%)
Phase 4Post-market surveillance
4,096(10.1%)
N/ANon-phased studies
6,621(16.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.6%

26137 of 31247 finished

Non-Completion Rate

16.4%

5110 ended early

Currently Active

4644

trials recruiting

Total Trials

40,617

all time

Status Distribution
Active(5989)
Completed(26137)
Terminated(5110)
Other(3381)

Detailed Status

Completed26137
Terminated3756
Recruiting3287
unknown3274
Active, not recruiting1357
Withdrawn1354

Development Timeline

Analytics

Development Status

Total Trials
40617
Active
4644
Success Rate
87.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 1557 (1.4%)
Phase 17935 (19.6%)
Phase 212598 (31.1%)
Phase 38711 (21.5%)
Phase 44096 (10.1%)
N/A6621 (16.3%)

Trials by Status

active_not_recruiting13573%
enrolling_by_invitation1190%
recruiting32878%
not_yet_recruiting12263%
unknown32748%
withdrawn13543%
completed2613764%
terminated37569%
suspended1070%

Recent Activity

Clinical Trials (40,617)

Showing 20 of 40,617 trialsScroll for more
NCT07535034Phase 2

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

Not Yet Recruiting
NCT05580562Phase 3

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Recruiting
NCT06972459Phase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Recruiting
NCT07532655Phase 1

A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants

Not Yet Recruiting
NCT05842174Phase 1

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

Recruiting
NCT01566188Not Applicable

Vascular Impact of Omega-3 in Metabolic Syndrome

Completed
NCT06511908Phase 2

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

Recruiting
NCT05075824Phase 2

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

Completed
NCT04519697Phase 1

Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease

Terminated
NCT07219043Phase 2

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

Recruiting
NCT04404439Phase 4

Treatment of Tinnitus With Migraine Medications

Completed
NCT07221227Phase 3

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Recruiting
NCT05713799Phase 2

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

Not Yet Recruiting
NCT06948097Phase 1

Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies

Not Yet Recruiting
NCT04519671Phase 1

Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease

Terminated
NCT05097287Phase 4

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

Active Not Recruiting
NCT05807139Phase 1

Spironolactone in Alcohol Use Disorder (SAUD)

Recruiting
NCT07486934Phase 3

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

Recruiting
NCT06699849Phase 2

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Recruiting
NCT05166889Phase 3

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

Completed

Drug Details

Intervention Type
DRUG
Total Trials
40,617